莫沙必利

莫沙必利（INN：mosapride）属于一种胃肠动力药，是选择性 5-HT4受体激动剂，其主要代谢产物 M1（des-p-fluorobenzyl mosaprideLi K, Jiang X, Xiong Z, Qin F, Zhao L. The tissue distribution and excretion study of mosapride and its active des-p-fluorobenzyl and 4'-N-oxide metabolites in rats by ultra-high performance liquid chromatography-tandem mass spectrometry method. Xenobiotica. 2020 Feb;50(2):115-124. doi: 10.1080/00498254.2019.1588410. Epub 2019 Mar 20. PMID 30883253.Aoki Y, Hakamata H, Igarashi Y, Uchida K, Kobayashi H, Hirayama N, Kotani A, Kusu F. Liquid chromatography-tandem mass spectrometric method for determination of mosapride citrate in equine tissues. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 15;858(1-2):135-42. doi: 10.1016/j.jchromb.2007.08.017. Epub 2007 Aug 22. PMID 17851144.）还具有 5HT3受体的竞争性拮抗作用，可加速人体整个胃肠道的排空。

莫沙必利用来治疗胃炎、胃食管反流病、功能性消化不良和肠易激综合征Mizuta Y, Shikuwa S, Isomoto H, Mishima R, Akazawa Y, Masuda J, Omagari K, Takeshima F, Kohno S. Recent insights into digestive motility in functional dyspepsia. Journal of Gastroenterology. 2006 Nov;41(11):1025-40.Kato S, Morie T, Yoshida N. Synthesis and biological activities of metabolites of mosapride, a new gastroprokinetic agent.Chemical and Pharmaceutical Bulletin (Tokyo). 1995 Apr;43(4):699-702.，也做為止吐劑，較不會誘發椎體外症候群。枸缘酸盐形式的莫沙必利，由大日本住友制药在1998年以加斯清为商品名上市销售。

參見
蕈毒鹼拮抗劑(Muscarinic antagonist、蕈毒鹼性受體拮抗劑)

引用

Category:消化道促動力藥
Category:血清素受体激动剂
Category:苯甲酰胺
Category:吗啉
Category:苯乙醚
Category:对氟苯基化合物
Category:氯苯衍生物